234 related articles for article (PubMed ID: 10468616)
1. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
VandenDriessche T; Vanslembrouck V; Goovaerts I; Zwinnen H; Vanderhaeghen ML; Collen D; Chuah MK
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10379-84. PubMed ID: 10468616
[TBL] [Abstract][Full Text] [Related]
2. Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice.
Park F
Hum Gene Ther; 2003 Oct; 14(15):1489-94. PubMed ID: 14577928
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
[TBL] [Abstract][Full Text] [Related]
4. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
6. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
Lipshutz GS; Sarkar R; Flebbe-Rehwaldt L; Kazazian H; Gaensler KM
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13324-9. PubMed ID: 10557319
[TBL] [Abstract][Full Text] [Related]
7. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.
Connelly S; Andrews JL; Gallo AM; Kayda DB; Qian J; Hoyer L; Kadan MJ; Gorziglia MI; Trapnell BC; McClelland A; Kaleko M
Blood; 1998 May; 91(9):3273-81. PubMed ID: 9558383
[TBL] [Abstract][Full Text] [Related]
8. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
Andrews JL; Weaver L; Kaleko M; Connelly S
Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
Van Damme A; Chuah MK; Dell'accio F; De Bari C; Luyten F; Collen D; VandenDriessche T
Haemophilia; 2003 Jan; 9(1):94-103. PubMed ID: 12558785
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
13. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
14. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
[TBL] [Abstract][Full Text] [Related]
15. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
16. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.
Chuah MK; VandenDriessche T; Morgan RA
Hum Gene Ther; 1995 Nov; 6(11):1363-77. PubMed ID: 8573610
[TBL] [Abstract][Full Text] [Related]
17. GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice.
Milani M; Canepari C; Assanelli S; Merlin S; Borroni E; Starinieri F; Biffi M; Russo F; Fabiano A; Zambroni D; Annoni A; Naldini L; Follenzi A; Cantore A
EMBO Mol Med; 2024 Jun; 16(6):1427-1450. PubMed ID: 38684862
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
[TBL] [Abstract][Full Text] [Related]
19. Codon optimization of human factor VIII cDNAs leads to high-level expression.
Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
[TBL] [Abstract][Full Text] [Related]
20. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector.
Reddy PS; Sakhuja K; Ganesh S; Yang L; Kayda D; Brann T; Pattison S; Golightly D; Idamakanti N; Pinkstaff A; Kaloss M; Barjot C; Chamberlain JS; Kaleko M; Connelly S
Mol Ther; 2002 Jan; 5(1):63-73. PubMed ID: 11786047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]